Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights,...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights,...
2023-11-20 07:00:00 ET Summary We maintain our sell rating due to the company's voluntary recall of its flagship product, Brexafemme, and concerns over manufacturing challenges. The recall has had a significant impact on SCYX stock price and raises doubts about its growth trajecto...
2023-11-14 10:18:51 ET More on SCYNEXIS Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) Seeking Alpha’s Quant Rating on SCYNEXIS Historical earnings data for SCYNEXIS For further details see: SCYNEXIS ...
IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advance Remediation strategies following the voluntary recall of BREXAFEMME ® and the MARIO study clinical hold are being evaluated ...
2023-11-13 17:13:11 ET More on SCYNEXIS Scynexis hit by FDA clinical hold on antifungal trials Scynexis recalling antifungal therapy on potential contamination For further details see: SCYNEXIS files to sell 32.5M shares
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired SCYNEXIS, Inc. (...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
SCYNEXIS Inc. (SCYX) is expected to report $0.29 for Q3 2023
JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation funge...
News, Short Squeeze, Breakout and More Instantly...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...